Opi­oid re­place­ment drug ap­proved

Pharmacy Daily - - Front Page -

THE Ther­a­peu­tic Goods Ad­min­is­tra­tion has granted Ca­mu­rus approval to mar­ket the first long-act­ing treat­ment of opi­oid de­pen­dence.

The com­pany’s lead products Bu­vi­dal Weekly and Bu­vi­dal Monthly are in­di­cated for main­te­nance treat­ment of opi­oid de­pen­dence within a frame­work of med­i­cal, so­cial and psy­choso­cial sup­port.

For­mu­lated with Ca­mu­rus’ Flu­idCrys­tal in­jec­tion de­pot tech­nol­ogy, Bu­vi­dal is a lipid-based so­lu­tion which, once in­jected, trans­forms into a nanos­truc­tured gel-like de­pot.

The de­pot slowly biode­grades over time, re­leas­ing buprenor­phine which blocks the drug-lik­ing ef­fect of opi­oids in the brain and re­duces with­drawal, crav­ing and pa­tient’s use of il­licit opi­oids.

Pro­fes­sor Ni­cholas Lintzeris, Di­rec­tor of Drug & Al­co­hol Ser­vices, Univer­sity of Syd­ney, said, “The in­tro­duc­tion of Bu­vi­dal rep­re­sents the most sig­nif­i­cant de­vel­op­ment in over 15 years of opi­oid de­pen­dence treat­ment in Aus­tralia”.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.